LiBBY Grant Notice of Award Received
Alzheimer’s Clinical Trials Consortium is excited to announce that we have received the official notice of award for the ACTC Life’s end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial. The LIBBY trial will evaulate a combination of CBD and THC as a treatment for agitation in participants with a diagnosis of dementia who are eligible for hospice and are experiencing agitation. Since there are currently no approved treatments or guidelines to assist clinicians in addressing end of life agitation in dementia, and the LiBBY trial hopes to fill this gap in treatment without subjecting participants to the side effects of typically prescribed medications. For more information on this project, please click here.